BioVex To Announce Updated Survival Data From A Phase II Clinical Study Of OncoVEX GM-CSF In Metastatic Melanoma - 0 views
-
Matti Narkia on 24 May 09BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 - June 2, 2009 in Orlando, F